Introduction
Gestational diabetes mellitus (GDM) is the most common metabolic disorder in pregnancy. The condition is considered to be associated with increased perinatal morbidity and mortality [6] , which may be reduced by adequate diagnosis and management. The diagnosis of GDM is generally established by means of an oral glucose tolerance test (OGTT) , that is regarded as abnormal on the basis of predefined criteria. The aim of treatment in gestational diabetic patients is to obtain normoglycemia, which usually requires dietary measures with or without insuline therapy. In an effort to study the efficacy of the glucose tolerance test to detect those patients with GDM who require therapeutic measures to maintain normoglycemia, we compared the results of a glucose tolerance test with those of a glucose profile consisting of three postprandial glucose values, and with pregnancy outcome.
Subjects and methods
During a two-year period, from September 1985 to August 1987, we prospectively studied 250 Caucasian pregnant women considered to be at risk for GDM. Each woman had one or more of the following risk factors: a past history of GDM, a previous macrosomic or hypoglycemic infant, a positive family history, age 35 years or more, obesity, recurrent glycosuria, or accelerated fetal growth in the present pregnancy. Patients with known type 1 or type 2 diabetes mellitus, and women with multiple pregnancy were excluded. In all subjects a 50-g OGTT was performed following three days of glucose loading with at least 50 g glucose/day and capillary blood was sampled at 0, 0.5, and 1 hour. On the same day one of the staff nurses taught the women how to take their own capillary blood samples at home. Samples were collected in prelabeled fluoride oxalate tubes, on the following day one hour after breakfast, lunch and dinner. Glucose levels were measured the next day in whole blood using the hexokinase method (Boehringer Mannheim). Only one 50-g OGTT and one home glucose profile (HGP) were obtained from each subject to be used for comparison. The gestational age at the time of testing ranged from 16 to 36 weeks, with a median of 29 weeks.
Curriculum vitae
The OGTT was considered to be abnormal if one or more of the glucose values exceeded the upper limits as used in our institution, of 5.3, 9.1 and 8.7 mmol/L at 0, 0.5 and 1.0 hour, respectively, prior to 28th weeks' gestation, and of 5.5, 8.4 and 9.2 mmol/L thereafter [4] . The home glucose profile (HOP) was considered abnormal if one or more of the glucose values exceeded the value of 7.0 mmol/L [4] . A diagnosis of GDM was rejected when both OGTT and glucose profile were normal, and no treatment was instituted. When both the OGTT and the glucose profile were abnormal, a diagnosis of GDM was made. These patients were treated with dietary measures alone or, if necessary to maintain glucose values at of below 7.0 mmol/L, in combination with insulin. When one of both tests was abnormal, the diagnosis of GDM as well as the necessity for therapeutic measures was considered to be questionable, and a third test was performed.
This third test was used as a gold standard, and consisted of a clinically monitored glucose profile (CGP). Subjects were on a standard hospital diet (approximately 40% fat, 45% glucose, 15% protein, 30 kcal/kg.day) during the test, and capillary whole blood samples were taken one hour after each of the three main meals. GDM was considered to be absent and no specific treatment was given if glucose values did not exceed the level of 7.0 mmol/L. Patients in whom one or more glucose concentrations exceeded the value of 7.0 mmol/L were considered to have gestational diabetes, and therapeutic measures were instituted.
Differences in relative frequencies between groups were tested with the X 2 -test, and a p value of < 0.05 was regarded as significant. 
Results
The glucose test results are shown in figure 1. Both OGTT and HGP were normal in 197 women and abnormal in 17 women, while in 36 women only one of the two tests was found to be abnormal. These 36 women were tested again, using the CDP as a gold standard. Of these 36 women, only 19 had an abnormal CGP and were treated with diet with or without additional insulin therapy.
Fetal outcome as related to the OGTT and HGP test results is presented in table I. An abnormal OGTT was associated with the birth of a largefor-gestational age infant (weight > 90th centile) in 6 of 39, or 15% of cases, a normal OGTT with 21 of 214 large infants (no significant difference). An abnormal HGP preceded the birth of a large infant in 7 of 31, or 23% of cases, while a normal HGP was associated with 20 of 219, or 9%, large-for-gestational age infants, again no significant difference. The frequency of occurrence of instrumental deliveries was similar between groups. Four perinatal deaths occurred (1.6%). In three of these cases both OGTT and HGP had been normal and fetal or neonatal death appeared to be unrelated to glucose metabolism (one second trimester birth due to cervical insufficiency, one stillbirth of a severely growth retarded fetus, one asphyxiated infant born after placental abruption). In the fourth case both OGTT and HGP had been abnormal. Despite treatment with diet and insulin, the infant had a birth weight of 4380 g at 39 weeks (> P 90). The infant was in good clinical condition and had normal glucose levels during the first 48 hours after delivery, but died suddenly on the third day after birth. Postmortem examination failed to demonstrate the cause of death.
Discussion
Patients with GDM tend to deliver large babies, which may increase the risk of perinatal morbidity [3] and mortality [6] . The most important risks are: prolonged labor and delivery, hyperbilirubinemia, traumatic injury and neonatal hypoglycemia [3] . In order to reduce these risks, considerable effort is put into the detection and treatment of GDM. However, no agreement exists about the criteria on which the diagnosis should be based, about the question how accurate the diagnosis can predict increased risks, or on the effectiveness of treatment to reduce those risks [2, 7] .
The diagnosis of GDM is usually based on a abnormal OGTT. However, important differences exist with regard to patient selection, optimum timing, dose and duration of glucose loading, site and frequency of sampling, method of glucose assay, and normal ranges [1] . An abnormal OGTT does not necessarily mean that glucose values under less unphysiologic circumstances, that is on a normal diet, are abnormal. In addition, healthy pregnant women at no increased risk of GDM have a 2.3% risk of an abnormal test if 2 standard deviations above the mean in uncomplicated pregnancy is used as a cut-off level. In the present study the OGTT was abnormal in 39 of 250 women, or 16%, at risk for GDM. However, 11 of these 39 women (or 28%) with a abnormal OGTT subsequently had two normal glucose day profiles (HGP and CGP). Consequently, the OGTT overestimated the occurrence of hyperglycemia by 28%.
Other investigators screen for GDM by sampling at one or several occasions during the day, either at random, or before and after one of the main meals, or after a glucose load [5] . Again, 2.3% of healthy pregnant women will have abnormal test results by statistical definition in many studies. In the present study, 11 of 219 women, or 5%, with a normal HGP, had both an abnormal OGTT and an abnormal CGP. This suggests that the HGP in this study underestimated the occurrence of hyperglycemia by 5%.
Even if one assumes that the OGTT overestimates by 28%, and the HGP underestimates by 5% the chance of hyperglycemia, this still leaves unanswered the question as to what extent mild to moderate hyperglycemia increases the risks in the perinatal period, or how effective treatment of such hyperglycemia is to prevent these risks. Our study cannot provide the answer to this question, because all women in whom hyperglycemia was identified, were treated. The percentages of large-for-gestational age infants, instrumental deliveries, low Apgar scores, and perinatal deaths, were slightly, but not significantly, higher than those in the normoglycemic, untreated group. Although this could indicate that treatment was indeed effective, alternative explanations are that the numbers were too small to allow valid statistical comparison, or that outcome would have been just as good without therapy. Twenty-one large-for-gestational age infants were born from 214 normoglycemic untreated mothers. This suggests that one cannot effectively identify the 10% largest infants in the population by screening for GDM.
The percentages of instrumental deliveries, low Apgar scores and perinatal deaths in the normoglycemic women are comparable to those in the population of pregnant women in our highrisk obstetric unit; they were apparently not related to birth weight. This suggests that in women considered to be at increased risk for GDM also other risk factors than poor glycemic control alone may contribute to a fetal outcome that is less favorable than that in the general population [6] . Although several authors have argued that treatment of GDM should result in improved out-come, the effect of treatment can only be demonstrated in a large randomized study in which the hyperglycemic controls remain untreated. Considering the inconvenience, anxiety and costs of glucose tolerance testing for the patient, a randomized controlled study of the efficacy of screening and treatment programs for GDM may be warranted and ethically justified.
Abstract
In an effort to assess the efficacy of the oral glucose tolerance test to detect patients with gestational diabetes mellitus who require therapeutic measures to maintain normoglycemia, we compared the results of an oral glucose tolerance test with those of a home glucose profile consisting of three postprandial glucose values in 250 pregnant women.
The OGTT overestimated the occurrence of hyperglycemia by 28%, while the home glucose profile underestimated the occurrence of hyperglycemia by 5%. Pregnancy outcome was not significantly different between spontaneously normoglycemic women and those who required therapy. One cannot effectively identify the ten percent largest infants in the population by screening for gestational diabetes. 
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